8月11日前,老兵和倡导者要求林业发展局批准MDMA协助的创伤后应激障碍治疗。 Veterans and advocates push for FDA approval of MDMA-assisted PTSD therapy by August 11th.

退伍军人和倡导者正在游说林业发展局在8月11日前批准MDMA协助治疗创伤后精神紧张症的治疗。 Veterans and advocates are lobbying the FDA to approve MDMA-assisted therapy for PTSD treatment by August 11th. 尽管林业发展局顾问小组在6月投票反对证据,但支持者认为摇头丸的活性成分MDMA填补了有效的创伤后精神紧张症治疗的空白。 Despite a panel of FDA advisors voting against the evidence in June, supporters argue that MDMA, the active ingredient in ecstasy, fills a gap in effective PTSD treatments. 林业发展局的决定可能受公众压力的影响,批准可以为进一步探讨各种精神卫生状况的精神病辅助治疗并使其合法化开创先例。 The FDA's decision may be influenced by public pressure, and approval could set a precedent for the further exploration and legalization of psychedelic-assisted treatments for various mental health conditions.